Skip to Main Content

Paper Details

12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.
Clin Infect Dis
47
2016
ARV, DCV, Daclatasvir, GT, HCV, HCV RNA, HIV, HIV-HCV, HIV-HCV Coinfection, HIV-HCV-, SOF, Sofosbuvir, abacavir, cirrhosis, daclatasvir, hepatitis C virus, human, human immunodeficiency virus, integrase, patients, sofosbuvir, tenofovir disoproxil fumarate
Author NameAffiliation
Moti RamgopalMidway Immunology and Research Center
Rafia Bhore
  • 1 - 2

Datasets

Release 1.2